Ewing tumour is characterized by speci®c chromosome translocations which fuse EWS to a subset of genes encoding ETS transcription factors, most frequently FLI-1. We report the analysis of the expression of various cell cycle regulators both in Ewing tumour derived cell lines and in dierent cellular models with either inducible or constitutive EWS-FLI-1 cDNA expression. In Ewing cell lines, cyclin D1, CDK4, Rb, p27 KIP1 and c-Myc were consistently highly expressed whereas p57 KIP2 expression levels were also observed in neuroblastoma NGP cells constitutively expressing EWS-FLI-1 as compared to parental cells. Analysis of the p57 KIP2 promoter indicated that EWS-FLI-1 downregulates, possibly through an indirect mechanism, the transcription of this gene. Finally, we show that ectopic expression of p57 KIP2 in Ewing cells blocks proliferation through a complete G1 arrest. These results suggest that the modulation of p57 KIP2 expression by EWS-FLI-1 is a fundamental step in Ewing tumorigenesis. Oncogene (2001) 20, 3258 ± 3265.
Introduction
The Ewing family of tumours includes tumours with various tissue localization and cell morphology characterized by the presence of speci®c fusions between EWS and members of the ETS family of transcription factors. The most frequent fusion gene links EWS and FLI-1 sequences and encodes a chimeric EWS-FLI-1 protein which includes the N-terminal transactivation domain of EWS and the C-terminal DNA binding domain of FLI-1 (Delattre et al., 1992) . EWS-FLI-1 can bind DNA with the same anity as FLI-1, however it activates transcription of reporter genes controlled by ETS sequences much more eciently than FLI-1. EWS-FLI-1 has the ability to transform NIH3T3 cells and this activity requires both the transactivation domain of EWS and the ETS-DNA binding domain of FLI-1 (May et al., 1993; Bailly et al., 1994; Mao et al., 1994) . These observations have suggested that EWS-FLI-1 transforms cells through the aberrant activation of speci®c target genes. Indeed, genes upregulated by EWS-FLI-1 have been identi®ed through dierential expression screening between EWS-FLI-1-transformed and normal NIH3T3 cells May et al., 1997; Arvand et al., 1998) . However, a direct role of EWS-FLI-1 on transcriptional activation of these genes has not been unambiguously demonstrated. Recent data suggest that the oncogenic role of EWS-FLI-1 is not restricted to activation of target genes. Indeed, its transforming activity is not strictly dependent upon the DNA binding domain, suggesting that the oncogenic activity of the fusion protein could also be mediated by protein-protein interactions (Jaishankar et al., 1999) . Moreover, EWS-FLI-1 can act as a transcriptional repressor as shown by its ability to downregulate, through a direct repressor eect, the promoter of the Transforming Growth Factor type II receptor (TGFBR2) (Hahm et al., 1999) . Other EWS-ETS fusion proteins observed in Ewing tumour (ET) also repress this promoter suggesting that the loss of the TGFb signalling pathway is an important step for the Ewing sarcoma tumorigenesis (Im et al., 2000) .
Although most human cancers harbour abnormalities of the G1/S transition, a link between EWS-FLI-1 and cell cycle regulators has not yet been described. To get additional insights into the mechanisms by which EWS-FLI-1 induces cell proliferation and oncogenesis, we report the analysis of the expression of cell cycle regulators in 13 Ewing cell lines and in two dierent cellular systems including a heavy metal inducible EWS-FLI-1 cDNA in Hela cells and neuroblastoma NGP cells constitutively expressing EWS-FLI-1. These results con®rm and extend previous data concerning cMyc (Bailly et al., 1994) and further show that EWS-FLI-1 downregulates the expression of p57
KIP2
. Therefore, EWS-FLI-1 controls two key regulators of cell growth and proliferation.
Results

Analysis of cell cycle regulators expression in Ewing cell lines
A total of 13 Ewing cell lines expressing dierent types of Ewing speci®c fusion proteins, being EWS-FLI-1 in 12 cases (®ve with a type 1, four a type 2 and three other types of EWS-FLI-1 fusions) and EWS-ERG in one case (Table 1) , were investigated. In addition to the presence of the speci®c EWS-ETS lesion, most cell lines had p53 and/or p16 INK4A genomic alterations (Table 1) . Indeed, 11 out of 13 cell lines demonstrated p53 mutations and four had homozygous deletion of the p16 INK4A exon 2 locus as determined by PCR ampli®ca-tion of this exon (data not shown). Protein extracts were Western blotted and probed with antibodies speci®c for cell cycle regulators (Table 1 and Figure  1 ). All cases without p16
INK4A deletion but one (EW7) expressed the p16 INK4A protein indicating that methylation of the p16 INK4A promoter, a silencing mechanism frequently observed in other tumour types, is probably not a major cause of inactivation of the p16 INK4A gene in Ewing tumour. p14 ARF , which is mainly encoded by the exon 2 of p16 INK4A and p15 INK4B were only expressed at low level in two cases each. MDM2 was expressed at various levels in all cell lines without an evident link with the presence of a p53 mutation and with the level of p14 ARF expression. In contrast, p21 CIP1 expression was correlated with p53 status since it was expressed in the two cell lines without p53 mutation and in only two of the 11 p53-mutated cell lines. This strong but not absolute correlation is in agreement with previous reports suggesting that p21 CIP1 can be activated by p53-independent pathways (for review see Gartel and Tyner, 1999 KIP2 was weakly expressed in only three cases (Figure 1a,b) .
Finally, c-Myc, E2F1, CDK4, cyclin D1 and both hypo and hyperphosphorylated forms of Rb were visualized in all cases.
Analysis of cell cycle regulators expression in cells with an inducible EWS-FLI-1 gene
The EWS-FLI-1 cDNA cloned under the control of the sheep metallothionein inducible promoter, was transfected in Hela cells. One clone (pMTEF) was selected based on an undetectable expression of the fusion protein in non-induced conditions and strong induction upon cadmium treatment (Figure 2a) . Analysis of the kinetics of the induction indicated that the EWS-FLI-1 protein was detectable 4 h after addition of 20 mM cadmium in the medium and reached at 8 ± 12 h an expression level similar to that of the endogeneous fusion protein in Ewing cell lines (Figure 2b ). An induction of 24 h was used to study the expression of the various aforementioned cell cycle regulators. In order to dierentiate the variation of expression linked to cadmium treatment and to EWS-FLI-1 induction, Western blot experiments were performed with protein extracts from induced or non-induced pMTEF cells and from Hela cells upon similar conditions. Similarly to b actin, the expression levels of Rb, E2F, CDK4, CDK6, MDM2, p21 The type of fusion refers to the exons from EWS and FLI-1 anking the junction. b mut indicates the presence of a p53 mutation (as determined by Kovar et al., 1993; Komuro et al., 1993; Hamelin et al., 1994) . c PCR analysis of p16 exon 2 was performed as reported by Xing et al. (1999) c-Myc was strongly upregulated whereas p57 KIP2 expression was completely downregulated upon EWS-FLI-1 induction. Finally, cyclin D1 was strongly upregulated by cadmium alone, therefore, the eect of EWS-FLI-1 could not be precisely investigated (Figure 2a ).
Expression of p57
KIP2 and c-Myc in stable EWS-FLI-1 expressing neuroblastoma cells KIP2 mRNAs together with the endogeneous TBP transcript as an internal control. They showed that c-Myc mRNA was induced whereas that of p57 KIP2 was reduced in the presence of EWS-FLI-1 both in the inducible Hela and in the constitutive NGP systems ( Figure 3 ). These results strongly suggested that modi®cations of c-Myc and p57 KIP2 occur through transcriptional regulation. Indeed, a previous study has indicated that c-Myc transcription is strongly upregulated by EWS-FLI-1, possibly through an indirect mechanism since speci®c binding of EWS-FLI-1 to the c-Myc promoter could not be demonstrated (Bailly et al., 1994) . We therefore performed similar analysis of the transcription regulation of the p57 KIP2 promoter.
EWS-FLI-1 downregulates the p57 KIP2 promoter
To study the possible role of EWS-FLI-1 on the p57 KIP2 promoter, the previously described c14F5 cosmid which contains the complete p57 KIP2 gene was used (Reid et al., 1996) . Four dierent luciferase vectors were constructed extending 72191, 71550, 7595 and 7165 ( Figure  4a ,b) upstream of the transcription initiation start site (Tokino et al., 1996) . These reporters were co-transfected in Hela cells with EWS-FLI-1 or FLI-1 expression vectors. For all four constructs a moderate (approximately twofold) but reproducible decrease of the luciferase activity was observed with EWS-FLI-1 whereas such a reduction was not detected for wild type FLI-1 (Figure 4c ). Similar levels of repression were obtained when CHO or SKNAS cells were used (data not shown). However, whatever the cells used or the amount of transfected EWS-FLI-1 the repression of transcription induced by EWS-FLI-1 never reached the basal level of a promoterless construct. These results strongly suggested that EWS-FLI-1 but not FLI-1 had a moderate repressive eect on the transcription of the p57 KIP2 promoter. The p57 KIP2 promoter contains a number of putative ETS binding sites (EBS). In particular, one such site (CGTTCCAC) is present in the 7165KIP2 construct (Figure 4b ). However, bandshift experiments indicated that EWS-FLI-1 did not bind to this site supporting the hypothesis that EWS-FLI-1 does not repress p57 KIP2 transcription through a direct interaction with this site. Table 1 is shown. The EWS-FLI-1 fusion proteins are shown on the top. The variety of the size of the proteins is fully consistent with the type of fusion transcripts indicated in Table 1 . The EW3 cell line expresses an EWS-ERG fusion which cannot be detected by the 7.3 antibody (Melot et al., 1997) . Detection of b actin (bottom) is used as an internal control for the amount of proteins. (b) p57 KIP2 is weakly expressed in ORS, EW7 and EW17 Ewing cell lines as compared to the neuroblastoma NGP cell line
Ectopic expression of p57 KIP2 blocks proliferation of Ewing cells
The Ewing EW24 cell line was transfected with either an expression vector encoding a GFP-p57 KIP2 fusion protein (Reynaud et al., 1999) or with a GFP control vector (pEGFP-C1, Clontech). In the days following transfection,¯uorescent cells were counted. Cells expressing GFP demonstrated a clear proliferation with progressive decrease of the¯uorescence of individual cells linked to dilution of the GFP vector in dividing cells. In contrast, when the GFP-p57 KIP2 expression vector was used, the number of¯uorescent cells did not increase and the intensity of¯uorescence of individual cells remained stable over time ( Figure  5a ). This experiment strongly suggested that GFPp57 KIP2 can block the proliferation of Ewing cells. To con®rm the eect of p57 KIP2 on the cell cycle, EW24 Ewing cells were cotransfected with a vector encoding puromycin resistance (pPUR) and either empty or p57 KIP2 encoding pcDNA. After selection of puromycin resistant cells and labelling with BrdU, the cell cycle was studied by¯ow cytometry. As compared to pPUR+pcDNA transfected cells, cells expressing p57 KIP2 exhibited a strong decrease in S phase and an increase in G1 (Figure 5b ). Similar results were obtained when another Ewing cell line (ORS) was used for these experiments (data not shown). Altogether, these results showed that p57 KIP2 expression is able to block the proliferation of Ewing cells through inhibition of entry into S phase. KIP2 were analysed by competitive RT ± PCR using coampli®cation of c-Myc or p57 KIP2 with TBP as an internal control
Discussion
In this study, our goal was to analyse the possible in¯uence of EWS-FLI-1 on the expression levels of various regulators of the cell cycle. The ideal system would have been to construct an inducible EWS-FLI-1 model within the parental cells giving rise to Ewing tumour. However, since presently the precise cellular origin of ET is not known, the expression of EWS-FLI-1 in such an appropriate system is not possible. We therefore analysed the expression of cell cycle regulators in the context of Ewing tumour cell lines and correlated these ®ndings with the expression level of the same regulators in two heterologous cellular models. These included an inducible EWS-FLI-1 expression system in Hela cells and a constitutive expression model in neuroblastoma cells. The expression levels of Cyclin D1, Rb, E2F1, CDK4, MDM2 and c-Myc were high in all ET cell lines tested, an observation compatible with a link between EWS-ETS fusion products and the expression of these proteins. However, apart from a strong induction of c-Myc, the expression levels of these proteins did not signi®cantly vary upon EWS-FLI-1 induction in pMTEF cells. c-Myc expression level was also considerably increased in NGP cells expressing EWS-FLI-1 as compared to parental cells. These results con®rm and extend previous experiments which showed that EWS-FLI-1 upregulates the c-Myc promoter, probably through an indirect mechanism (Bailly et al., 1994 promoter and its precise mechanism of action. It has been shown recently that p57 KIP2 , similarly to p21
CIP1
, has concentration-dependent eects on cyclin-CDK complexes. At low doses, these proteins promote the assembly of catalytically active complexes whereas, at higher concentrations, they inhibit kinase activity of these complexes (Lin et al., 1996; Hashimoto et al., 1998) . In this respect it is noteworthy that EWS-FLI-1 does not lead to full repression of the p57 KIP2 promoter, an observation in agreement with the detection of a weak p57 KIP2 expression in a subset of Ewing cell lines.
The crucial role of p57 KIP2 downregulation in the oncogenic properties of Ewing cells is strongly supported by the observation that ectopic expression of p57 KIP2 completely abolished proliferation of these cells through the induction of a G1 arrest. This eect is consistent with the role of p57 KIP2 as an inhibitor of G1 cyclin-dependent kinases. Indeed, it has been shown that p57 KIP2 can induce a G1-arrest through association with cyclin-CDK complexes and subsequent inhibition of the phosphorylation of the Rb protein (Lee et al., 1995; Matsuoka et al., 1995) . The observation that p57 KIP2 can block S phase entry in Ewing cells indicates that the dowstream eectors of this pathway, including Rb, are functional. p57 KIP2 is suspected to play a role in dierent cancers. Indeed, it is localized within the 11p15 chromosome region which has been shown to undergo genomic imprinting, the maternal allele being predominantly expressed (Matsuoka et al., 1996) . p57 KIP2 loss-offunction may be involved in Wilms tumour which demonstrates frequent loss of the maternal allele at 11p15 (Hatada et al., 1996a) . It could also be important in the oncogenesis of a number of human malignancies which demonstrates loss-of-heterozygosity of this chromosome region and/or low expression levels (Feinberg, 1999a) . A direct link between p57 KIP2 and oncogenesis is also provided by the observation of constitutional p57 KIP2 mutations in a subset of patients with BeckwithWiedmann syndrome, a condition which is associated with a susceptibility to the development of childhood cancers (Hatada et al., 1996b) .
This study together with recent data from other laboratories indicate that the expression of EWS-FLI-1 leads to major abnormalities of the regulation of the G1 to S transition through distinct but convergent pathways. First, it strongly upregulates c-Myc which in turn is expected to activate CDK4 and Id2 transcription (Hermeking et al., 2000; Lasorella et al., 2000) . Accordingly, CDK4 (Table 1 ) and Id2 (data not shown), are highly expressed in Ewing cells. Secondly, the repression of the promoter of the TGFBR2 impairs the TGFb pathway which controls cell cycle progression, in particular through the SMAD cascade which regulates the transcription of CDK inhibitors (Hahm et al., 1999 ; Alexandrow and , an inhibitor of G1 cyclin-CDK complexes. Altogether, these dierent modi®cations are expected to converge on a functional inactivation of Rb. This combined eect probably constitutes a critical step in the oncogenesis of Ewing tumour. A direct repression of EWS-FLI-1 on the TGFBR2 has been strongly suggested (Hahm et al., 1999) . Further studies should elucidate the precise mechanisms of the control of c-Myc and p57 KIP2 transcription by EWS-FLI-1.
Materials and methods
Cell lines
The PMT/EF plasmid was obtained by cloning the EWS-FLI-1 type 1 open reading frame into the HindIII restriction site of pMT-CB6+ vector which contains the sheep metallothionein promoter and a Neo resistance gene (Sumarsono et al., 1996) . This plasmid was used to stably transfect Hela cells in the presence of 2 mg/ml of G418. To generate the NGP-EF cell lines, the neuroblastoma NGP9A Tr1 (NGP) cell line was infected with a previously described EWS-FLI-1 encoding retroviral vector (Lessnick et al., 1995) . After selection in the presence of 600 mg/ml of G418, stable clones were isolated for further characterization. The NGP-NEO cell line was generated by transfecting the pMAM-neo expression vector onto NGP9A Tr1 by Superfect method (Qiagen).
A673, HeLa, COS-7, CHO, SKNAS and pMTEF cells were propagated in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with antibiotics and 10% foetal calf serum. All other Ewing cell lines were maintained in RPMI 1640 medium supplemented with 10% foetal calf serum (Life Technologies) and antibiotics (penicillin/streptomycin from Life Technologies). NGP and derived cell lines were grown in RPMI 1640 medium supplemented with 20% foetal calf serum and antibiotics.
p57
Kip2 promoter reporter vectors and luciferase assay A 4.8 kb EcoRI ± HindIII fragment containing the p57 KIP2 gene was excised from the c14F5 cosmid (Reid et al., 1996) and cloned into bluescript vector. The 72191KIP2 luciferase vector was constructed by cloning a SacI ± NheI promoter fragment into the pGL3 basic (Promega). The 71550KIP2, 7595KIP2 and 7165KIP2 constructs were derived from the 72191KIP2. 2.5610 5 Hela, CHO or SKNAS cells were seeded in 60-mm petri dishes and transfected by calcium phosphate method 24 h later with 1 mg of the reporter plasmid and the indicated amounts of expression plasmids. Forty-eight hours post-transfection, cells were lysed and assayed for luciferase activity according to the manufacturer's instructions (Promega).
Electrophoretic mobility shift assay
Transfection of COS-7 cells with an EWS-FLI-1 encoding vector, preparation of nuclear extracts and conditions for electrophoretic mobility shift assay were performed as previously described (Melot et al., 1997 ) using a p57 KIP2 probe (GCTGGGCGTTCCACAGGCCA).
Flow cytometry analysis
EW24 Ewing cells were cotransfected by eectene method (Qiagen) with pPUR (puromycin resistance plasmid from Clontech) and p57 KIP2 encoding vector (Reynaud et al., 1999) or pcDNA3 empty vector in a 1 to 10 ratio. One day after transfection, cells were selected for 24 to 48 h in the presence of 1 mg/ml of puromycin then labelled with 30 mM of BrdU for 30 min at 378C. FACS analysis was performed as previously described (Remvikos et al., 1991) . After washing in PBS 16 and ®xation in ethanol 70%, cells were digested with 0.5 mg/ml pepsine for 20 min at 378C and treated with 2 N HCl for 20 min at room temperature. Cells incubated with a rat monoclonal antibody anti-BrdU (Abcys) for 1 h at room temperature, then with a FITC-conjugated anti-rat secondary antibody (Southern Biotechnology Associates, Inc.) were used for cell cycle analysis.
Antibodies and Western blot analysis
Cellular extracts were prepared either directly in sample buer or in RIPA without SDS depending on the antibody used. Seventy-®ve mg of proteins were loaded on SDSpolyacrylamide gels, separated by electrophoresis then electro-transferred onto nitrocellulose membranes. After staining with Ponceau red, membranes were blocked with 25 mM Tris-HCl pH 8, 125 mM NaCl, 0.15% tween 20 and 5% non fat milk for 1 h at room temperature, incubated for 1 h 30 min with primary antibodies at room temperature then washed and incubated for 1 h with horseradish peroxydaseconjugated anti-rabbit or anti-mouse secondary antibodies diluted 1/3000 (Amersham) and detected by an enhanced chemiluminescence system (Roche) according to the manufacturer's instructions.
Monoclonal anti-p21 CIP1 (Transduction Laboratories), -p53 (provided by T Soussi, Institut Curie Paris, France), -FLI-1 (Melot et al., 1997) , and polyclonal anti-HA, -p57
Kip2 , -p18
INK4C
, -p27 KIP1 (obtained from Santa Cruz Biotechnology), -c-Myc (Euromedex), and cyclin D1 antibodies (Euromedex) were used to analyse extracts prepared in sample buer. Monoclonal anti-E2F1 (KH95 from Santa Cruz Biotechnology), -Rb (G3-245 from Pharmigen) and -MDM2 (provided by T Soussi, Institut Curie Paris, France) and polyclonal anti-p16 INK4A , -p14 ARF , -p15 INK4B (obtained from Santa Cruz Biotechnology) antibodies were used for extracts prepared in RIPA without SDS.
All the membranes were probed with a monoclonal anti-b actin AC74 antibody (supplied by Sigma) diluted 1/20 000 as an internal control for expression.
Competitive RT ± PCR
Total mRNA treated with DNAse were extracted from Hela and NGP derived cell lines with S.N.A.P.
TM total isolation kit (In Vitrogen). For the NGP-EF cell lines, EWS-FLI-1 expression was monitored using the 22.14 EWS primer: GCACCTCCATCCTACCCTCCT and the previously described FLI.11 primer (Peter et al., 1995) .
Relative expression of c-Myc and p57 Kip2 were assessed by co-ampli®cation with TBP as internal control. The primer sequences for TBP were as described by Gil Diez de Medina et al. (1998) , the primer sequences of c-Myc were: GACATGGTGAACCAGAGTTTC (sense) and GTGTCT-CCTCATGGAGCAC (reverse), the primer sequences of p57 Kip2 were obtained from Clontech. The PCR reactions were performed by using 15 pmoles of each primer for 30 cycles: 948C for 30 s, 608C for 30 s and 728C for 30 s.
